ScripFinance Watch has kept a close eye on venture capital financings in 2025 because of the notable drop in mega-rounds of $100m or more, and there have been none since the last private company edition,
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. B+L Bolsters Ophthalmology With Acquis
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Busy Moderna Inks Gene-Editing Pact Wit